Higher priced drugs are not cost effective for diabetic macular edema, US study finds.
Seattle.
Michael
M
McCarthy
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use; D057186:Comparative Effectiveness Research; D003362:Cost-Benefit Analysis; D003930:Diabetic Retinopathy / Q000150:complications*; D016527:Drug Costs; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D000069579:Ranibizumab / Q000191:economics / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000191:economics* / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab